CN102049048B - 治疗或预防的方法 - Google Patents

治疗或预防的方法 Download PDF

Info

Publication number
CN102049048B
CN102049048B CN2010105444424A CN201010544442A CN102049048B CN 102049048 B CN102049048 B CN 102049048B CN 2010105444424 A CN2010105444424 A CN 2010105444424A CN 201010544442 A CN201010544442 A CN 201010544442A CN 102049048 B CN102049048 B CN 102049048B
Authority
CN
China
Prior art keywords
alkyl
replacement
phenyl
benzyl
neuropathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2010105444424A
Other languages
English (en)
Chinese (zh)
Other versions
CN102049048A (zh
Inventor
M·T·史密斯
B·D·韦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Spinifex Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004907332A external-priority patent/AU2004907332A0/en
Application filed by Spinifex Pharmaceuticals Pty Ltd filed Critical Spinifex Pharmaceuticals Pty Ltd
Publication of CN102049048A publication Critical patent/CN102049048A/zh
Application granted granted Critical
Publication of CN102049048B publication Critical patent/CN102049048B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
CN2010105444424A 2004-12-24 2005-12-23 治疗或预防的方法 Expired - Fee Related CN102049048B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004907332 2004-12-24
AU2004907332A AU2004907332A0 (en) 2004-12-24 Method of Treatment or Prophylaxis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2005800441997A Division CN101087619B (zh) 2004-12-24 2005-12-23 治疗或预防的方法

Publications (2)

Publication Number Publication Date
CN102049048A CN102049048A (zh) 2011-05-11
CN102049048B true CN102049048B (zh) 2013-12-25

Family

ID=36601295

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2005800441997A Expired - Fee Related CN101087619B (zh) 2004-12-24 2005-12-23 治疗或预防的方法
CN201210208621.XA Expired - Fee Related CN102861019B (zh) 2004-12-24 2005-12-23 治疗或预防神经性疼痛的药物
CN2010105444424A Expired - Fee Related CN102049048B (zh) 2004-12-24 2005-12-23 治疗或预防的方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN2005800441997A Expired - Fee Related CN101087619B (zh) 2004-12-24 2005-12-23 治疗或预防的方法
CN201210208621.XA Expired - Fee Related CN102861019B (zh) 2004-12-24 2005-12-23 治疗或预防神经性疼痛的药物

Country Status (16)

Country Link
US (5) US7795275B2 (enExample)
EP (3) EP1830869B1 (enExample)
JP (1) JP4966202B2 (enExample)
CN (3) CN101087619B (enExample)
CY (1) CY1114424T1 (enExample)
DK (1) DK1830869T3 (enExample)
ES (1) ES2425567T3 (enExample)
HR (1) HRP20130738T1 (enExample)
ME (1) ME01597B (enExample)
NZ (1) NZ555334A (enExample)
PL (1) PL1830869T3 (enExample)
PT (1) PT1830869E (enExample)
RS (1) RS52927B (enExample)
SI (1) SI1830869T1 (enExample)
WO (1) WO2006066361A1 (enExample)
ZA (3) ZA200704909B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1830869B1 (en) 2004-12-24 2013-05-22 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
JP5230595B2 (ja) 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
JP2010505881A (ja) * 2006-10-05 2010-02-25 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼインヒビターとして使用するための二環式窒素含有複素環式化合物
US20090105283A1 (en) * 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US7828840B2 (en) 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
US20100267752A1 (en) * 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
EP2350029A1 (en) * 2008-10-15 2011-08-03 Gilead Sciences, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
US9095587B2 (en) 2010-01-19 2015-08-04 Spinifex Pharmaceuticals Pty Ltd Methods and compositions for improved nerve conduction velocity
DE102010013075A1 (de) 2010-03-26 2011-09-29 B. Braun Melsungen Ag Antimikrobielle Wundauflage
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
HUE028620T2 (en) 2010-07-21 2016-12-28 Novartis Ag Tetrahydroisoquinoline derivative salt and solvates
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CA2846187A1 (en) 2011-08-23 2013-02-28 Endo Pharmaceuticals Inc. Pyrimido-pyridazinone compounds and use thereof
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
PL2800738T3 (pl) 2012-01-06 2020-10-19 Novartis Ag Związki heterocykliczne i sposoby ich stosowania
NZ627560A (en) * 2012-01-25 2016-08-26 Novartis Ag Heterocyclic piperazine compounds and methods for their use
PT2807171T (pt) 2012-01-25 2020-11-03 Novartis Ag Compostos heterocíclicos e métodos para a sua utilização
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
CN105358532B (zh) 2013-07-08 2019-07-23 诺华股份有限公司 杂环化合物和它们的使用方法
BR112016006171A2 (pt) 2013-09-30 2020-05-19 Fmc Corporation formulações de espuma e dispositivo para sua entrega
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MX370099B (es) 2014-03-26 2019-12-02 Astex Therapeutics Ltd Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer.
HUE053653T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR inhibitor és IGF1R inhibitor kombinációi
UY36181A (es) 2014-06-24 2016-09-30 Fmc Corp Formulaciones de espumas y concentrados emulsionables
JP6667551B2 (ja) 2015-01-13 2020-03-18 ノバルティス アーゲー アンジオテンシンｉｉ２型拮抗薬としてのピロリジン誘導体
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2016142867A1 (en) 2015-03-12 2016-09-15 Novartis Ag Heterocyclic compounds and methods for their use
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN106478502B (zh) * 2015-08-29 2021-04-27 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
JP6898919B2 (ja) 2015-09-23 2021-07-07 ヤンセン ファーマシューティカ エヌ．ベー． 新規化合物
WO2017050865A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
MA44111A (fr) 2015-12-23 2018-10-31 Fmc Corp Traitement in situ de semences dans un sillon
WO2018001997A1 (en) 2016-06-27 2018-01-04 Ratiopharm Gmbh Crystalline calcium salt of (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid
JP2019514862A (ja) 2017-03-23 2019-06-06 ノバルティス アーゲー （ｓ）−２−（ジフェニルアセチル）−１，２，３，４−テトラヒドロ−６−メトキシ−５−（フェニルメトキシ）−３−イソキノリンカルボン酸ナトリウムの無水結晶形
CN117503775A (zh) 2017-04-28 2024-02-06 自由生物有限公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
EP3620454B1 (en) * 2017-06-09 2021-05-05 Shandong Danhong Pharmaceutical Co., Ltd. Carboxylic acid derivative as at2r receptor antagonist
GB201710906D0 (en) * 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
WO2019161781A1 (zh) * 2018-02-23 2019-08-29 北京泰德制药股份有限公司 受体抑制剂、包含其的药物组合物及其用途
CN111801318B (zh) * 2018-03-23 2024-01-02 北京泰德制药股份有限公司 受体抑制剂、包含其的药物组合物及其用途
EP3820498A1 (en) * 2018-06-14 2021-05-19 University College Cork-National University of Ireland Cork Peptide for disease treatment
WO2020012266A1 (en) 2018-07-12 2020-01-16 Novartis Ag Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase
US20240368133A1 (en) 2021-07-30 2024-11-07 Confo Therapeutics N.V. Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling
CA3254395A1 (en) 2022-05-17 2023-11-23 Eli Lilly And Company AT2R'S ANTAGONISTS AND THEIR USES

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812462A (en) * 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
WO1992020661A1 (en) * 1991-05-22 1992-11-26 Merck & Co., Inc. N, n-diacylpiperazines
US5204354A (en) * 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
WO1993023378A1 (en) * 1992-05-19 1993-11-25 Warner-Lambert Company Substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin ii receptor antagonist properties
CN1331590A (zh) * 1998-12-23 2002-01-16 诺瓦提斯公司 At－1受体拮抗剂或at－2受体调节剂在治疗与at－1或at－2受体增加有关的疾病中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3531485A (en) 1967-08-14 1970-09-29 American Home Prod Aryl-substituted diazabicycloalkanes
US3957795A (en) 1974-01-28 1976-05-18 Delmar Chemicals Limited Novel cyclopentene and cyclopentane derivatives
US3975795A (en) 1975-01-20 1976-08-24 Union Carbide Corporation Product stuffing apparatus and method
US5091390A (en) 1990-09-20 1992-02-25 E. I. Du Pont De Nemours And Company Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs
JP3208139B2 (ja) 1990-10-02 2001-09-10 ワーナー−ランバート・コンパニー アンギオテンシン▲ｉｉ▼アンタゴニスト
US5385894A (en) * 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
US5238942A (en) 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
CA2132544C (en) 1992-04-13 2005-10-18 Frank Carey Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
GB9208116D0 (en) 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
US5344830A (en) 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
EP0673369A1 (de) 1992-12-11 1995-09-27 Novartis AG Substituierte benzazepinone
US5395844A (en) 1993-06-10 1995-03-07 The Du Pont Merck Pharmaceutical Company Imidazole 5-position substituted angiotensin II antagonists
US5348955A (en) 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
US5338740A (en) 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
AP9400651A0 (en) 1993-07-15 1995-12-30 Pfizer Azacyclic-heterocyclic compounds as angiotensin II receptor antagonists.
US5409926A (en) 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
US5610165A (en) 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
FR2739625B1 (fr) 1995-10-09 1997-12-05 Atochem Elf Sa Copolymeres hydrosolubles associatifs triblocs
GB2323783A (en) 1997-04-02 1998-10-07 Ferring Bv Group Holdings Inhibitors of farnesyl protein transferase
WO1999007413A1 (en) 1997-08-11 1999-02-18 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
US6277839B1 (en) 1998-10-07 2001-08-21 Merck Frosst Canada & Co. Biphenylene lactams as prostaglandin receptor ligands
EP1237888B1 (en) * 1999-12-15 2006-09-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2001043761A2 (en) 1999-12-16 2001-06-21 University Of Southern California Methods for treating and preventing damage to mucosal tissue
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
CA2415697A1 (en) 2000-07-13 2002-01-24 James C. Forbes Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
EP1333824B1 (en) 2000-11-17 2005-09-07 Warner-Lambert Company LLC Treatment of sexual dysfunction with bombesin receptor antagonists
EG23054A (en) 2001-01-22 2004-02-29 Sankyo Co Pyrrole derivatives their preparation and their therapeutic uses
WO2002060439A1 (en) 2001-01-29 2002-08-08 Takeda Chemical Industries, Ltd. Analgesic and antiinflammatory drugs
WO2002060923A2 (en) 2001-01-29 2002-08-08 Cognetix, Inc. B-superfamily conotoxins
US7067261B2 (en) 2001-12-14 2006-06-27 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
WO2003064414A1 (en) 2002-01-29 2003-08-07 Vicore Pharma Ab. Tricyclic compounds useful as angiotensin ii agonists
TWI259079B (en) 2002-02-08 2006-08-01 Merck & Co Inc N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives
AU2003209851A1 (en) 2002-03-20 2003-09-29 The University Of Queensland Method of treatment and/or prophylaxis
US7348348B2 (en) 2002-04-30 2008-03-25 Merck & Co. Inc. Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
JP2005530778A (ja) 2002-05-17 2005-10-13 フォースト・ファーマシューティカルス 神経障害の予防および／または治療のための方法
WO2003101381A2 (en) 2002-05-29 2003-12-11 Merck & Co., Inc. 1,2 diamido cycloalkyl sodium channel blockers
GB0212412D0 (en) 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
US20040258757A1 (en) 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
DE10300973A1 (de) 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
PA8597401A1 (es) 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
WO2004099248A2 (en) 2003-05-05 2004-11-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
EP1830869B1 (en) 2004-12-24 2013-05-22 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812462A (en) * 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
WO1992020661A1 (en) * 1991-05-22 1992-11-26 Merck & Co., Inc. N, n-diacylpiperazines
US5204354A (en) * 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
WO1993023378A1 (en) * 1992-05-19 1993-11-25 Warner-Lambert Company Substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin ii receptor antagonist properties
CN1331590A (zh) * 1998-12-23 2002-01-16 诺瓦提斯公司 At－1受体拮抗剂或at－2受体调节剂在治疗与at－1或at－2受体增加有关的疾病中的应用

Also Published As

Publication number Publication date
US20140228362A1 (en) 2014-08-14
SI1830869T1 (sl) 2013-12-31
US20060223741A1 (en) 2006-10-05
EP1830869A1 (en) 2007-09-12
JP2008531470A (ja) 2008-08-14
CN102049048A (zh) 2011-05-11
ZA201207322B (en) 2017-06-28
US8404686B2 (en) 2013-03-26
CN102861019A (zh) 2013-01-09
EP1830869B1 (en) 2013-05-22
DK1830869T3 (da) 2013-08-26
PL1830869T3 (pl) 2013-11-29
US20130296350A1 (en) 2013-11-07
US7795275B2 (en) 2010-09-14
NZ555334A (en) 2010-05-28
CN102861019B (zh) 2016-05-25
EP1830869A4 (en) 2010-08-11
PT1830869E (pt) 2013-08-22
US8492382B2 (en) 2013-07-23
HRP20130738T1 (hr) 2013-10-25
CY1114424T1 (el) 2016-10-05
JP4966202B2 (ja) 2012-07-04
ZA200704909B (en) 2012-12-27
US20120004259A1 (en) 2012-01-05
ME01597B (me) 2014-09-20
EP2650010A1 (en) 2013-10-16
WO2006066361A1 (en) 2006-06-29
ZA201207323B (en) 2017-06-28
ES2425567T3 (es) 2013-10-16
CN101087619A (zh) 2007-12-12
EP2650011A1 (en) 2013-10-16
HK1103364A1 (en) 2007-12-21
RS52927B (sr) 2014-02-28
US9018207B2 (en) 2015-04-28
CN101087619B (zh) 2012-12-05
US20110318329A1 (en) 2011-12-29
US8722675B2 (en) 2014-05-13

Similar Documents

Publication Publication Date Title
CN102049048B (zh) 治疗或预防的方法
CN102885818A (zh) 治疗或预防炎性痛的方法
US11191798B2 (en) Extracts of Andrographis paniculata, methods for preparation and use thereof
Melis et al. PD-168077, a selective dopamine D4 receptor agonist, induces penile erection when injected into the paraventricular nucleus of male rats
AU2019338236B2 (en) A GABAA receptor ligand
JP6998657B2 (ja) 幹細胞調節ｉｉ
Zhang et al. A cyclic peptide retards the proliferation of DU145 prostate cancer cells in vitro and in vivo through inhibition of FGFR2
KR20240001703A (ko) 유비퀴틴 특이적 펩티다제 22 (usp22)의 억제제 및 질환 및 장애를 치료하기 위한 그의 용도
AU2005318882B2 (en) Method of treatment or prophylaxis
HK40057209B (en) A gabaa receptor ligand
HK40057209A (en) A gabaa receptor ligand
US20100317578A1 (en) Method of protecting against stroke through the use of a delta opioid peptide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20151225

Address after: Basel

Patentee after: Novartis Ag

Address before: Vitoria Australia

Patentee before: Spinifex Pharmaceuticals Pty Ltd.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131225

Termination date: 20181223

CF01 Termination of patent right due to non-payment of annual fee